Symbolbild · KI-generiert
Rakovina Therapeutics Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Company description as published by the issuer via TMX Money.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Rakovina Therapeutics Inc. | RKV | TSXV | 2 Mio. USD |
| Zero Candida Technologies Inc. | ZCT | TSXV | 2 Mio. USD |
| Fountain Asset Corp. | FA | TSXV | 2 Mio. USD |
| Cannibble Food-Tech Ltd | PLCN | CSE | 2 Mio. USD |
| Therma Bright Inc. | THRM | TSXV | 2 Mio. USD |
| CordovaCann Corp. | CDVA | CSE | 2 Mio. USD |
| Quest PharmaTech Inc. | QPT | TSXV | 2 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.